The impact of BCL-2/MYC protein expression and gene abnormality on primary central nervous system diffuse large B-cell lymphoma.

We determined the effects of the BCL-2, C-MYC, and BCL-6 gene aberrations and their protein expressions on the prognosis of primary central nervous system diffuse B-cell lymphoma (PCNS-DLBCL) patients. The pathological and clinical information of 47 immunocompetent patients was reviewed, and the immunohistochemical markers for BCL2, CD10, BCL6, MUM1, and MYC were reevaluated. Genetic abnormalities included increased copy number, translocation, gene amplification, and double aberration and were detected by fluorescence in situ hybridization (FISH). A survival analysis showed that elevated protein levels in the cerebrospinal fluid (CSF), increased the IPI score, and EBV infection adversely affected survival. However, high BCL2 (≥70%) and positive MYC expressions (≥40%) showed no significant influence on survival or BCL-2 gene abnormality, and BCL2/MYC double expression and BCL-2/C-MYC double aberrations were associated with adverse outcomes for PCNS-DLBCL patients. IJCEP